Follow us Facebook Icon


01 February, 2024 - Press Release

New Phase 3 Trial Data Confirm the Uniquely High Efficacy and Good Safety Profile of the R21/Matrix-M™ Malaria Vaccine in African Children

Phase 3 Trial data results of The R21/Matrix-M™ vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax’s Matrix-M™ adjuvant has confirmed high efficacy and supported regulatory approvals and licensure in several African countries. Read more...

23 January, 2024 - Press Release

Serum Institute of India joins CEPI global network to boost production of affordable outbreak vaccines

The world’s largest vaccine manufacturer, the Serum Institute of India Pvt. Ltd (SII), is joining a growing CEPI network of vaccine producers in the Global South to support more rapid, agile, and equitable responses to future public health disease outbreaks. Read more...

Cyrus Poonawalla

Dr. Cyrus S. Poonawalla

Chairman and Managing Director
Mr. Adar C. Poonawalla

Mr. Adar C. Poonawalla

Natasha Poonawalla

Mrs. Natasha A. Poonawalla

Executive Director - Serum Institute of India
Chairperson - Villoo Poonawalla Foundation


Poonawalla Group

The Cyrus Poonawalla Group of Companies headquartered in Pune, India are a diversified group with business interests that include Pharmaceuticals & Biotechnology, Finance, Clean Energy, Hospitality & Realty and Aviation.